The risk of PML from natalizumab - Authors' reply

Lancet Neurol. 2019 Mar;18(3):230-231. doi: 10.1016/S1474-4422(19)30022-5. Epub 2019 Feb 12.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • JC Virus / immunology*
  • Leukoencephalopathy, Progressive Multifocal*
  • Multiple Sclerosis*
  • Natalizumab
  • Retrospective Studies

Substances

  • Natalizumab